Novartis to Acquire MorphoSys for US$2.9 B to Expand Oncology Pipeline
By Lalit Mishra
Pharma Deals Review: Vol 2024 Issue 2 (Table of Contents)
Published: 10 Feb-2024
DOI: 10.3833/pdr.v2024.i2.2853 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a significant move towards bolstering its oncology portfolio, Novartis has agreed to acquire MorphoSys for €68 per share, reflecting an enterprise value of approximately US$2...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS